Tag Archive for: TCR-T cell therapy

After meeting the primary endpoints of a pivotal Phase II trial, UK-based Adaptimmune Ltd. is submitting an FDA Biologics License Application for its autologous T-cell receptor therapy (TCR-T) Lete-cel (letetresgene autoleucel).